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ABSTRACT
A viable rim of tumor cells surrounding central necrosis always exists and leads 
to tumor recurrence after vascular disrupting treatment (VDT). A novel necrosis 
targeted radiotherapy (NTRT) using iodine-131-labeled hypericin (131I-Hyp) was 
specifically designed to treat viable tumor rim and improve tumor control after VDT 
in rabbit models of multifocal VX2 tumors. NTRT was administered 24 hours after VDT. 
Tumor growth was significantly slowed down by NTRT with a smaller tumor volume 
and a prolonged tumor doubling time (14.4 vs. 5.7 days), as followed by in vivo 
magnetic resonance imaging over 12 days. The viable tumor rims were well inhibited 
in NTRT group compared with single VDT control group, as showed on tumor cross 
sections at day 12 (1 vs. 3.7 in area). High targetability of 131I-Hyp to tumor necrosis 
was demonstrated by in vivo SPECT as high uptake in tumor regions lasting over 9 
days with 4.26 to 98 times higher radioactivity for necrosis versus the viable tumor 
and other organs by gamma counting, and with ratios of 7.7–11.7 and 10.5–13.7 for 
necrosis over peri-tumor tissue by autoradiography and fluorescence microscopy, 
respectively. In conclusion, NTRT improved the anticancer efficacy of VDT in rabbits 
with VX2 tumors.
INTRODUCTION
Vascular disrupting treatment (VDT) has been 
considered a potentially important option for cancer 
therapy [1-3]. Vascular disrupting agents (VDAs) target 
the established tumor blood vessels rapidly and selectively, 
resulting in widespread ischemia and necrosis of the tumor 
[4, 5]. However, in clinical trials, minimal objective tumor 
responses were noted [1, 3, 6]. Experimental and clinical 
observations have demonstrated significant but transient 
reductions in tumor perfusion [6, 7]. A rim of viable tumor 
cells survived at the periphery, despite more than 90% of 
the central region of tumor experiencing rapid necrosis 
after administration of VDAs [8]. Therefore, these 
viable tumor cells are essential to tumor recurrence and 
metastasis. Re-growth and metastasis instead of primary 
tumor growth were believed to be the key contributors to 
the reduced overall survival benefit of cancer patients [9]. 
Efforts have been made to overcome the resistance 
of tumors to VDAs. Some treatment modalities such as 
radiotherapy, chemotherapy, immunoradiotherapy, or 
antiangiogenic drugs have been complementarily used 
to treat the surviving tumor rim [10-13]. Although short-
term enhanced tumor controls were observed in some 
of the studies, no substantial progress has been made in 
overcoming viable rim-induced cancer recurrence to date. 
The necrosis-targeted therapeutic strategy was 
proposed based on the studies of necrosis-avid contrast 
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agents (NACAs) [14]. Hypericin (Hyp), a natural small 
molecular compound extracted from St. John’s wort 
(Hypericum perforatum), was recently recognized as an 
NACA with powerful necrosis affinity [15-18]. In addition 
to its reported anti-viral, anti-tumor and antidepressant 
activities [19], Hyp has other two properties: one is 
photosensitivity, which permits the application of Hyp in 
fluoroscopy and photodynamic therapy [20-21]; the other 
is that Hyp can be radioiodinated promptly, efficiently and 
persistently [15-18, 22]. In previous preclinical studies, 
radioiodinated Hyp has been used in the diagnosis of 
myocardial infarction and discrimination of therapeutic 
necrosis from residual tumors, with target-to-nontarget 
ratios of approximately 30–80, which are much higher 
than those with the ever-discovered specific agents [16- 
18]. Thus, we assume that iodine-131-labeled hypericin 
(131I-Hyp) may selectively accumulate in tumor necrosis 
induced by VDAs and deliver high-energy beta particles 
to destroy the surrounding remaining malignant viable 
cells. The working principle of the novel necrosis-targeted 
radiotherapy (NTRT) is illustrated in Fig. 1.
The purpose of this study was to validate the new 
therapeutic strategy with NTRT in rabbit VX2 tumor 
models. Based on experiments in small rodents [23-25], 
we show for the first time that such medium-sized animal 
models can be used to verify the properties of NTRT. 
Furthermore, a more clinically relevant multifocal tumor 
model (in both the muscle and liver) was used to imitate 
the primary tumor coexisting with metastasis, which could 
simulate the conditions of clinical patients receiving VDT 
[1, 3, 6, 7, 10-13]. 
RESULTS
General conditions
The rabbit models of muscle and liver VX2 tumors 
were successfully established in all animals enrolled in 
the present study. All of rabbits survived the anesthesia, 
surgical procedures, drug injection, tumor growth and in 
vivo imaging sessions. Tumor necrosis was successfully 
induced with CA4P in all of the rabbits in groups B and 
C. 131I-Hyp was formulated with a labeling rate of 99.6% 
and was successfully injected intravenously in all of the 
rabbits in group C.
Figure 1: St. John’s wort and Necrosis Targeted Radiotherapy (NTRT). A. St. John’s wort is a yellow-flowering plant of the genus 
Hypericum, which can be purified into hypericin (Hyp). B. Hyp has the properties of being highly radioiodinated with an iodogen method. 
C. Hyp gives red fluorescence under UV light. D. Schematic diagram of NTRT. After vascular disrupting treatment, the tumor (a) becomes 
centrally necrotic on a large scale accompanied by a thin viable rim (b) because of the different blood supplies. Intravenously administered 
131I-Hyp may selectively reside in the necrosis and deliver highly intensive beta particles that efficiently kill peripheral viable malignant 
cells (c). Finally, the whole tumor may be destroyed (d). By contrast, the viable rim will eventually progress into recurrence if no effective 
intervening measures are taken (e). 
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Tumor changes on dynamic MR imaging
The tumors in the livers (Fig. 3A, a-c) and muscles 
(Fig. 3A, a’-c’) were clearly shown on contrast-enhanced 
T1-weighed MR images and demonstrated similar changes 
on imaging among the different groups. At baseline, the 
tumors in each group appeared to have similar sizes, round 
or oval shapes and moderate enhancement (Fig. 3A, a1-
c1, a’1-c’1). Twenty-four hours after the first injection 
of CA4P, the enhancement was sharply decreased in the 
center of the tumors in groups B and C, accompanied 
with residual enhanced rims (Fig. 3A, b2, c2, b’2, c’2). 
The corresponding histological results verified that the 
imaging changes were caused by ischemic central necrosis 
and residual peripheral tumor blood vessels. There was no 
change in group A on MR images between the baseline and 
24 h (Fig. 3A, a1, a2, a’1, a’2). By the second injection of 
131I-Hyp, the tumor growth in group C was well inhibited 
and maintained a stable in size until the endpoint (Fig. 3A, 
c3-c5, c’3-c’5). The tumors showed no enhancement with 
only thin and intermittently enhanced rims, findings that 
were speculatively attributed to beta irradiation of tumors 
by 131I-Hyp as supported by SPECT images. By contrast, 
the tumors in groups A (Fig. 3A, a3-a5, a’3-a’5) and B 
(Fig. 3A, b3-b5, b’3-b’5) grew rapidly with the tumor 
size progressively becoming larger than that in group C. 
Irregularly enhanced thick rims suggestive of viable tumor 
tissue were shown in group B at later time points (Fig. 3A, 
b3-b5, b’3-b’5). 
Tumor volume and tumor doubling time
As shown in Fig. 3B, the tumor volumes displayed 
no difference among the groups at baseline (2512±655, 
2343±738 and 1694±377 mm3 in group A, B and C, p > 
0.05). The tumors grew rapidly in groups A and B but 
slowly in group C, with no significant difference in tumor 
volumes among the groups at day 1 (3227±684, 2681±823 
and 2087±414 mm3 in groups A, B and C, respectively; p 
> 0.05) and day 4 (4990±882, 3656±1033 and 2502±397 
mm3 in groups A, B and C, respectively; p > 0.05). With 
further follow up, the tumor volumes were significantly 
larger in groups A and B than those in group C at day 8 
(8452±1021, 6220±1214 and 2872±457 mm3 in group A, 
B and C, respectively; p < 0.05; A vs. B, p > 0.05; A vs. 
C, p < 0.05; B vs. C, p < 0.05) and day 12 (12823±1237, 
10012±1730 and 3670±968 mm3 in groups A, B and C, 
respectively; p < 0.05; A vs. B, p > 0.05; A vs. C, p < 0.05; 
B vs. C, p < 0.05). TDT (Fig. 3C) was significant longer 
in group C (14.4±8.6 days) than that in group A (4.9±1.4 
days) and group B (5.7±1.8 days) between day 12 and 
baseline (p<0.01 among the 3 groups, A vs. B, p > 0.05; A 
vs. C, p < 0.01; B vs. C, p < 0.01).
Macroscopic histopathology and area of viable 
rim
Macroscopically, central necrosis, viable tumor rim 
and peritumoral tissues could be easily discriminated on 
the resected cross-sections of the split tumor specimen 
Figure 2: Flow diagram of the experimental procedures in rabbits with implanted bifocal VX2 tumors on both the 
liver and right leg. (VDA, vascular disrupting agent; Hyp, hypericin; PBS, phosphate-buffered saline; DMSO, Dimethyl sulfoxide)
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in group B and C (Fig. 4). The tumors in groups B 
were significantly larger with thicker viable tumor rims 
than those in group C, which were consistent with MRI 
findings. By analysis of the Adobe Photoshop CS5 
Extended 12.0 software, the mean gross tumor area 
in group B was 1.98 times larger than that in group C 
(5.94±4.96 vs. 3±2.76, p < 0.05). Furthermore, the mean 
area of viable rim was 3.7 times larger in group B than 
in group C (3.7±3.15 vs. 1±1.08, p < 0.05). However, 
the mean area of central necrosis was of no difference 
between the two groups (2.24±1.81 vs. 2±1.68, p > 0.05). 
It indicated that viable rim control by irradiation led to 
ideal whole tumor volume control. 
Figure 3: Dynamic MRI following up of representative tumor-bearing animals in each group. A. The enhanced T1-
weighted MR images (a1-c1, a’1-c’1) at baseline showed that the oval tumors on the liver (black arrows) and leg (white arrows) in each 
group were similar in size and enhanced to the same extent. Twenty-four hours after the first injection, the enhancement was shut down in 
the center of the tumors in groups B and C (b2, b’2 and c2, c’2) compared with the tumors in group A (a2, a’2). By the second injection, 
the tumors in group C became stable in volume and were maintained as non-enhanced centrally throughout the follow-up period (c3-c5, 
c’3-c’5). By contrast, the tumors in groups A and B grew faster with larger tumor volumes (a3-a5, a’3-a’5 and b3-b5, b’3-b’5) than those in 
group C. The central non-enhanced necrosis appeared with thicker, irregularly enhanced rims in group B (b3-b5, b’3-b’5). B. The growth 
curve of tumors at different time points showed no difference in tumor volume among the 3 groups at baseline. The tumors grew fastest in 
group A, and tumor growth was the lowest in group C. The tumor volumes were significantly larger in group A and B than those in group C 
at day 8 and day 12. C. The mean TDT in group C was significantly longer than that in group A and B. *p < 0.05, ** p < 0.01 
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In vivo SPECT and postmortem gamma counting
Two days after injection of 131I-Hyp (day 3), the 
planar static and tomographic images showed strong 
radioactive concentration or hot spots at tumor regions 
(Fig. 5A, white and black arrows) on the liver and right 
leg of the animals in group C. Additionally, abundant 
radioactivity was detected in the intestinal tract (Fig. 
5A, black arrowhead), which was considered a major 
excretion pathway of Hyp. Over time, the tumor regions 
showed a persistently high concentration of radioactivity, 
while 131I-Hyp was washed out from intestines. Compared 
with the images at day 3, those at day 9 (about one half-
life of 131I) showed equally strong hot points at tumor 
regions (Fig. 5B, white and black arrows) but significantly 
reduced radioactivity at intestinal regions (Fig. 5B, black 
arrowhead). The tumor to intestine ratio of radioactive 
intensity at day 9 (18.8±7.3) was 5 times of that at day 3 
(3.7±2.1).
The results of postmortem gamma counting at day 
12 showed that the radioactivity in necrotic tumors was 
much higher than that in viable tumors and other organs 
(Fig. 5C). The radioactivity of necrotic tumors (0.98±0.24 
ID%/g) was 4.26 times that of viable tumors (0.23±0.10 
ID%/g, p<0.01) and 4.45 times that of the liver (0.22±0.10 
ID%/g), followed by the lung (0.06±0.03 ID%/g), kidney 
(0.05±0.02 ID%/g), intestine (0.03±0.02 ID%/g), heart 
(0.03±0.02 ID%/g), stomach (0.03±0.02 ID%/g), thyroid 
(0.03±0.01 ID%/g), blood (0.03±0.01 ID%/g), colon 
(0.02±0.03 ID%/g), skin (0.02±0.01 ID%/g), muscle 
(0.02±0.01 ID%/g) and brain (0.01±0.01 ID%/g) (p < 
0.01 for all organs compared with necrotic tumors). The 
radioactivity in viable tumors and the liver was also 
significantly higher than that in other organs (p < 0.01).
Autoradiography and fluorescence microscopy
The necrosis avidity of 131I-Hyp was validated 
postmortem using autoradiography and fluorescence 
microscopy. The animals only in group C were subjected 
to analyses. The tumors appeared nearly complete necrosis 
on macroscopic specimens. Only very thin viable rims 
could be seen in some cases. Tumors were sampled 
for autoradiography and fluorescence microscopy. 
Corresponding to the H&E sections (Fig. 6A), color-coded 
autoradiography (Fig. 6B) visually displayed radioactivity 
distribution among necrosis, viable rim and peritumoral 
tissue with clear borders. The central necrosis (red color) 
showed much stronger radioactivity than the viable tumor 
rim (green color) and peritumoral muscular tissue (blue 
color). A better proof of the necrosis avidity of 131I-Hyp 
was that dotted necrotic foci (white and black arrows in 
Fig. 6A and 6B) within viable tumors also appeared as 
strong radioactivity of red color. Quantitative analysis 
(Fig.6G and 6H) showed the radioactive intensity of 
necrosis (247±139 CNT) was approximately 6.3 times 
higher than that of tumors (39±23 CNT, p < 0.01 vs. 
necrosis), 7.8 times higher than that of peritumoral liver 
(32±22 CNT, p < 0.01 vs. necrosis, p > 0.05 vs. tumor) and 
11.7 times higher than that of peritumoral muscle (21±11 
CNT, p < 0.01 vs. necrosis, p < 0.05 vs. tumor), with the 
ratios of necrosis/tumor/liver and necrosis/tumor/muscle 
as high as 7.7/1.2/1 and 11.7/1.8/1, respectively.
To visualize in greater detail the selective retention 
of 131I-Hyp in tumor necrosis, intratumoral distribution 
was analyzed by fluorescence microscopy. Necrosis, 
viable tumor and peritumoral tissues were distinguished 
by H&E staining (Fig. 6 C and 6D), showing different 
patterns on microscopic images. To compare the 
fluorescence distribution, microscopy was focused on 
the borders between different tissues. Fluoromicroscopic 
images revealed distinct fluorescence intensity in necrosis 
and viable tumors, and peritumoral tissues (Fig. 6E and 
6F), with necrosis/tumor/liver and necrosis/tumor/muscle 
ratios of 10.5/ 2.2/1 and 13.7/1.8/1, respectively (Fig. 6J 
and 6K). 
DISCUSSION
The new therapeutic strategy of complementary 
necrosis targeted radiotherapy (NTRT) was validated in 
the present study in rabbit VX2 tumor models mimicking 
a primary tumor at one site (e.g., muscle) with metastasis 
to another site (e.g., liver). The results indicated that the 
residual viable tumor rim around necrosis induced by a 
VDT could be well controlled by NTRT. To the best of our 
knowledge, therapeutics or NTRT specifically designed 
to treat a viable tumor rim after VDT has not yet been 
reported in rabbit VX2 tumor models. 
Using the “soil-to-seeds” principle, such a sequential 
targeting theragnostic modality was proposed and 
evaluated in rodents in 2011 [23]. It was speculated that 
the proliferative parenchyma of mutational cancer cells 
(seeds) are intrinsically resistant to targeted therapeutic 
attacks, whereas the supportive stroma of connective 
tissues (soil) are more genomically stable and easier to 
target. To further develop this dual targeting anticancer 
approach, in the current study, we successfully verified its 
efficacy and safety in rabbit VX2 tumor models of virtual 
primary and metastatic tumors. Among patients who 
receive systematic targeting therapy, more than half of 
them had metastases besides the primary tumors [1, 3, 6, 
7, 10-13]. Thus, this rabbit tumor model representatively 
imitated the clinical conditions of oncological patients. 
Furthermore, besides the therapeutic application, in 
vivo SPECT imaging might also allow the identification 
or monitoring of any known or unknown primary 
or metastatic lesions during treatment, follow up for 
therapeutic progress, and assessment of patient prognosis. 
Hence, NTRT has been regarded as a new targeting 
theragnostic approach [26-28].
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Figure 4: Macroscopic view of split tumor and measurement of viable rim area. A & B. The macroscopic photos showed that 
central necrosis, viable tumor rim and peritumoral tissues could be easily discriminated on the representative split tumor specimen in group 
B and C. The tumor in group B (A) was bigger and with thicker viable rim significantly than that in group C (B) The tumor and central 
necorsis (orange area) was delineated by the software of Adobe Photoshop CS5 Extended 12.0. The area of viable rim (yellow area) was 
drawn from area difference of tumor and central necrosis. C. By quantitative analysis the mean area of viable rim in group B was 3.7 times 
larger than that in group C (*p < 0.05). There was no significance (n.s.) in area of central necrosis between the two groups. The whole tumor 
area in group B was 1.98 times larger than that in group C (*p < 0.05). This indicated that inhibition of viable rim led to better tumor control. 
Figure 5: SPECT and gamma counting. A & B. The planar static and tomographic images of SPECT at day 3 (A) and day 9 (B) 
showed the persistently strong radioactivity focused on tumor regions (white and black arrows) in the liver and right leg. Strong radioactivity 
also appeared in the intestinal region (black arrowheads) at day 3 (A) and was obviously weakened at day 9 (B) indicative of the excretion 
pathway for 131I-Hyp. C. Box and whisker plots quantitatively showed the bio-distribution of 131I-Hyp in different tissues of the animals in 
group C at day 12 (11 days after the injection of 131I-Hyp). **The injected dose per gram of necrotic tumor was significantly higher than 
that of the viable tumor, liver and other organs (p < 0.01). *The injected dose per gram of viable tumor and liver was significantly higher 
than that of other organs (p < 0.05).
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The properties of NTRT were evaluated regarding 
two major aspects. The first is the strong targetability of 
131I-Hyp to central necrosis of the tumor, a finding that 
was verified by in vivo SPECT, ex vivo gamma counting, 
autoradiography and fluorescence microscopy. The second 
is the superb tumoricidal efficacy of the combined use of 
CA4P and 131I-Hyp that was evidenced by the dynamic 
MR images and corresponding histopathology after only a 
single episode of NTRT administration. 
An ideal targeting drug should have the properties 
of prompt target homing, persistent target residence and 
a high target-to-nontarget ratio. As a necrosis targeted 
agent, Hyp has shown a prominent targetability to tumor 
necrosis [16, 17, 23, 24, 26-28]. The targeting property 
Figure 6: Autoradiography and fluorescence microscopy of the tumors in group C. A & B.The tumor harvested from 
the leg of the rabbit in group C including necrosis, viable tumor rim and muscle was prepared as serial cryostat sections. The digital 
photographs of H&E (A) and corresponding autoradiography (B) sections showed the distribution of radioactivity intensity (necrosis>viable 
tumor>muscle). The dotted necrotic foci (black and white arrows) within the viable rim also revealed high intensity of radioactivity. The 
microscopic views were focused on the borders between necrosis, viable tumor rim and muscle (red frames). C-F. The light. (C & D) and 
corresponding fluorescence (E & F). microscopic graphs showed the distribution of fluorescence intensity (necrosis>viable tumor>muscle). 
G-J.The quantitative analysis showed the radioactivity (G & H) and intensity of fluorescence (I & J) was significantly stronger and higher 
in necrosis than those in viable tumor and peri-tumor tissues (muscle and liver). ** The radioactivity and intensity of fluorescence was 
significantly higher in necrosis than those in viable tumor, liver and muscle (p < 0.01). *The radioactivity and intensity of fluorescence was 
higher in viable tumor than those in muscle (p < 0.05). (H&E, hematoxylin and eosin; Auto-Rx, autoradiography; N, necrosis; T, tumor, 
M, muscle)
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of 131I-Hyp was verified in the present rabbit VX2 tumor 
model in two ways. The first is the detected gamma rays 
emitted from 131I, demonstrating in vivo as intensive and 
persistent hot-spots on tumor regions on SPECT scanning 
for at least 9 days and ex vivo as high gamma ray counts 
and as highly radioactive intratumoral necrotic zones on 
autoradiography at day 12. The second is the recorded 
coexisting red fluorescence emitted by Hyp in tumor 
necrosis. The highly concordant 131I and Hyp distribution 
in necrosis, tumor and peritumoral tissues also proved 
the stable conjugation of 131I and Hyp in the body. These 
results were consistent with those of previous studies in 
rats and mice. In a rat model of liver rhabdomyosarcoma-1 
(R1), 131I-Hyp was found to accumulate in tumor necrotic 
regions at 3.13% ID/g, corresponding to a target-to-
liver activity ratio of over 20 on day 8 after injection 
[23]. In mice carrying subcutaneous radiation-induced 
fibrosarcoma (RIF-1), a high concentration of 131I-Hyp was 
retained in tumor necrotic regions over 30 days, indicating 
long-term in vivo stability and targetability [23, 24]. 
The data from the above small and medium animal 
models demonstrated that 131I-Hyp is a potent agent for 
targeting necrotic tumors and appears superior to another 
radioiodinated agents used in tumor necrosis treatment 
(TNT). For instance, 131I-labeled chimeric monoclonal 
antibody (131I-mAb) was, until now, the only reported 
agent for TNT that targets a universal nuclear antigen 
histone [29, 30]. During TNT, only 0.001%–0.01% ID/g 
of 131I-mAb was found in treated tumors, resulting in a 
much lower targetability than that with 131I-Hyp [23, 31]. 
Furthermore, the poor pharmacokinetic profile, low tumor 
uptake owing to its large molecular mass, insufficient 
density of target antigens on tumor spots, as well as 
short serum half-life, limited the clinical use of 131I-mAb 
(32-34). 131I-Hyp could potentially expand the scope of 
TNT by introducing low-molecular-weight compounds 
without immunogenicity, bone marrow uptake and 
myelosuppression [16], important dose-limiting factors of 
TNT antibodies [27, 35]. Therefore, NTRT with 131I-Hyp 
could indicate substantial improvement in TNT. 
A high and enduring concentration of 131I-Hyp in 
tumoral necrosis was responsible for the observed tumor 
control with NTRT. In group C, 0.98% ID/g of 131I-Hyp 
was found in necrotic tumors at day 12, a finding that is 
estimated to correspond to a cumulative dose of more 
than 2000 Gy. This radiation dose to the tumors was 
much higher than the minimum radiation dose of 50 Gy 
that was necessary to achieve a therapeutic response in 
most neoplasms [31]. Furthermore, 131I emitted β particles 
with a maximum penetration of 2.0 mm in tissues, a 
thickness that is far beyond the typical thickness of the 
remaining viable tumor of approximately 20–100 μm 
following CA4P treatment [27]. These observations can 
explain why NTRT in group C, compared with single 
administration of CA4P, well inhibited the tumor growth 
(about one-third of the volume in group B) and prolonged 
TDT (approximately 3 times that of group B) during the 
12-day observation period. On the other hand, the tumor 
inhibition by a single dose of CA4P (group B) was not 
remarkable compared with the blank control (group A), 
results that were similar to those of reported clinical trials 
[11]. The lack of a significant tumor inhibitory effect in 
group B might be explained by hypoxia-induced tumor 
aggression following CA4P injection. With the regulation 
of hypoxia-inducible factor 1α (HIF-1α), expression 
of the angiogenic gene is activated to elevate the level 
of vascular endothelial growth factor, and endothelial 
progenitor cells are increased, subsequently promoting 
tumor neovascularization [36]. Additionally, the peripheral 
remnant tumor cells are supplied by nontumoral blood 
vessels and are oxygen saturated. Following the injection 
of CA4P, these tumor cells rapidly proliferate and become 
more sensitive to radiation, a condition that is readily 
suitable for NTRT with 131I-Hyp. 
The biodistribution and excretion of 131I-Hyp in 
rabbits were documented in the present study, and the 
results were similar to previous results in rodents [23, 
24, 27]. On SPECT imaging, besides the tumor regions, 
the intestines showed relatively high radioactivity at 
day 3 but not at day 9. Thus, the liver-bile-intestine axis 
was believed to be the excretion pathway of 131I-Hyp. 
However, relatively high gamma counts were still detected 
in rabbit liver at day 12, a result that was different from 
that in rodents [23]. The cause may be due to interspecies 
variations in uptake, metabolism and excretion of 131I-Hyp. 
Therefore, further studies in other animal species, 
particularly larger-sized animals such as canines or swine, 
are deemed necessary before the application in humans. 
NTRT was well tolerated by all of the rabbits 
without the side effects commonly seen with other 
chemo- or radiotherapies. As described previously [17], 
radioiodinated Hyp is mainly taken up by the liver and 
quickly eliminated via bile with a short biological half-life, 
minimizing hepatobiliary injuries and preventing the risk 
of renal damage, which is often seen with radioiodinated 
antibodies or peptides. 
To extend the application scope, NTRT could be 
suitable to improve other necrosis-induced therapies, 
such as thermal ablation, transcatheter embolization, 
external beam radiotherapy and most systematic molecular 
targeting treatments. For instance, radiofrequency ablation 
(RFA) has become a standard treatment for liver cancer, 
renal cancer, thyroid cancer and some malignant bone 
tumors. One problem of RFA is the heat sinking effect 
that protects the tumor cells near vessels from thermal 
damage, leading to tumor recurrence [37]. Regarding the 
central necrosis induced by RFA, NTRT might act as a 
workable supplement to kill the residual cancer cells and 
prevent tumor recurrence, thus tackling the heat sinking 
effect caused by peritumoral blood flow. To further 
develop this novel approach of NTRT, other species of 
animals such as canines, swine or nonhuman primates 
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will be used to verify the modality’s safety and efficacy. 
For application of the NTRT in humans, after approval by 
the ethical committee and regulatory authorities, clinical 
trials in cancer patients with primary and metastatic solid 
malignancies, particularly those that failed with existing 
therapies, will be considered as indications. 
There are several limitations in this study. First, the 
simultaneous implantation of VX2 tumors in the leg and 
liver may in fact not perfectly mimic the presence of a 
liver metastasis. Second, whether the approach of NTRT 
might prolong animal survival was not observed in this 
study. Third, the stability of the formulation of 131I-Hyp in 
body and toxicity need to be further studied.
In conclusion, 131I-Hyp was proven to be a promising 
necrosis-targeted agent in rabbit VX2 tumor models, 
with a smaller molecular weight, better in vivo stability, 
higher concentration in necrosis and fast clearance from 
other organs. As a complementary therapeutic modality, 
NTRT well improved the anticancer efficacy of VDT with 
a simple procedure, a high tumor volume control rate 
and low toxicity, and the procedure could be imaged and 
monitored by clinical MRI and SPECT suites. The final 
application of 131I-Hyp may provide a new option in our 
anticancer armamentarium. 
MATERIALS AND METHODS
Animal model
The protocol for this animal experimentation was 
approved by the Animal Care and Use Committee of 
China Medical University. Healthy New Zealand white 
rabbits weighing 3 kg were provided and maintained by 
the laboratory animal center of the institute. Fresh VX2 
tumors harvested from the tumor-bearing rabbits were cut 
into 1-mm3 blocks, which were inoculated into the right 
leg and liver of the recipient rabbits using a CT-guided 
percutaneous puncture implantation method [38]. The 
rabbits were maintained for 2 weeks to develop solitary 
lesions with a diameter of approximately 2 centimeters 
in both the liver and right leg. The tumor models were 
evaluated by magnetic resonance imaging (MRI).
Anesthesia
The rabbits were anesthetized by intramuscular 
injection of 3% soluble pentobarbitone (0.5 mg/kg; Sigma, 
St. Louis, MO, USA) for tumor implantation procedures 
and in vivo imaging examination.
Drug preparation and administration
Combretastatin A4 phosphate (CA4P), 5-[(2R)-
2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2- 
methoxyphenol (Sigma, St. Louis, MO, USA), as a typical 
VDA, was diluted in phosphate- buffered saline (PBS) at 
a concentration of 10 mg/ml and intravenously injected at 
10 mg/kg of body weight. [38, 39]
Hypericin, 4,5,7,4’,5’,7’ -hexahydroxy-2,2’-
dimethylnaphthodianthrone (with a purity 99%; 
Biopurify Phytochemicals Ltd., Chengdu, China; http//
www.biopurify.com) was diluted in dimethyl sulfoxide 
(DMSO, Sigma, St. Louis, MO, USA) at 1 mg/ml and 
radioiodinated by 131I (Na131I, HTA Co.,Ltd., Beijing, 
China) using an iodogen-coating method (a standard 
electrophilic substitution reaction) [15,22] . Briefly, 
by using an Iodogen (1,3,4,6-tetrachloro-3α,6α-
diphenylglycouril) tube (Molde, Haimen Jiangsu, China), 
radioiodination was conducted by adding 900 MBq of 
Na131I, 50 μl of 0.5 M phosphate buffer solution (pH 7.4), 
and then 2mg of Hyp. The mixture was incubated for 20 
minutes, and the reaction was terminated by removal of 
the reaction mixture. The labeling rate was determined 
by ascending paper chromatography using Xinhua Filter 
paper grade No. 1 and 0.01 N HCl. Then the agent was 
intravenously injected at a dose of 74 MBq/kg.
Study protocol
Thyroid was blocked in all rabbits by feeding 
Lugol’s solution (5% iodine and 10% potassium iodide 
mixed in distilled water; total iodine content of 126.5 
mg/mL) from 3 days before the experiments. Twenty-
seven tumor-bearing rabbits were divided into 3 groups 
randomly (9 rabbits in each group). The animals in each 
group received sequential intravenous injections at a 24-
hour interval. Animals in Group A (blank control group) 
received the two solvents (PBS and DMSO). Animals in 
group B (VDA control group) received CA4P and DMSO. 
Animals in group C (NTRT group) received CA4P and 
131I-Hyp. A 24-h interval between injections allowed the 
complete formation of necrosis and optimal accessibility to 
the latter due to partial recovery of tumor vascularization 
[22-24, 39, 40]. An animal in each group was executed 
24 hours after the first injection to verify tumor necrosis 
induced by CA4P. MRI and SPECT were performed in 
vivo at different time points. All 24 animals with bifocal 
VX2 tumors (one in the muscle and the other in the liver) 
in the three groups were executed immediately after the 
last examination at day 12. Postmortem techniques of 
histopathology, gamma counting, autoradiography and 
fluorescence microscopy were used. The study protocol is 
illustrated in Fig. 2. 
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MR imaging
MRI was performed using a 3.0-T MR unit (Signa 
HDx; General Electric Medical Systems, USA) with a 
maximum gradient strength of 40 mT/m equipped with a 
HD Quadrature Knee/Foot Coil. Initially, a T1-weighted 
(T1W) spin-echo (SE) sequence with axial, coronal, and 
sagittal images was used as a localizer. Next, enhanced 
T1W axial images (TR/TE, 200/5.8 ms; FOV, 160×160 
mm; imaging acquisition matrix, 256×192) were obtained 
with a section thickness of 3.0 mm and an intersection 
gap of 1.0 mm after intravenous bolus injection of 
gadodiamide (GE Healthcare AS, USA) at 0.1 mmol/kg.
The tumor volume was calculated using a dedicated 
workstation (Advantage Workstation, ADW 4.5; GE 
Medical Systems, USA). Using an operator-defined 
region of interest (ROI), the area of tumor was manually 
delineated on each tumor-containing slice. The total area 
of tumor for the slices was calculated after summation 
and then was multiplied by the slice thickness plus gap 
to obtain the total tumor volume according to the formula 
[I] [38,41]:
Tumor Volume = Σ Tumor area on each tumor 
containing slice × (Slice thickness + Gap) [I]
The tumor doubling time (TDT) was calculated 
based on the formula [II] [42]:
TDT = (T-T0)×log2 /(logV-logV0) [II], where (T-T0) 
indicates the time interval between two measurements, and 
V0 and V denote the tumor volume at the two points of 
measurement.
The tumors in the muscle and liver were averaged 
by groups for tumor volume analysis. 
SPECT imaging
SPECT imaging was performed 2 days and 8 days 
after injection of 131I-Hyp (on day 3 and day 9). Images 
were acquired using a dual-head SPECT system (Symbia 
T2; SIEMENS, Malvern, PA, USA) equipped with a high-
energy, low-resolution collimator. The imaging acquisition 
parameters included an energy peak of 340 Kev±20 %, 
a magnification of 1.00 and a matrix of 128×128. Planar 
static images were acquired for 50K counts or 5 min, 
whichever was completed first. Tomographic images were 
acquired from 30 projections collected for 40 s each over 
180° using a 64 × 64 matrix. Data were reconstructed 
using the iterative mode (SyngoMI 2009; SIEMENS, 
Malvern, PA, USA). Flash 3D was set to 6. The iteration 
was 8, and Gaussian was 6 mm. Radioactive hot spots 
were searched on planar static and tomographic images.
Measurement of viable rim
After sacrifice of an animal at day 12, the tumor 
together with its surrounding tissue was resected and 
swift into the surrounding of -20°C for 60 minutes. Then, 
the tumor was split into halves along its axial direction. 
The profiles of the tumor were taken photos digitally 
and analyzed with Adobe Photoshop CS5 Extended 
12.0 (CA, USA). The areas of necrosis and entire tumor 
were delineated and calculated. Area of viable rim was 
the difference of area of entire tumor subtracting area of 
central necrosis, as showed by formula [III]. 
Area viable rim = Area entire tumor - Area central necrosis [III]
Gamma counting 
Tumor (central necrosis and viable rim), peritumoral 
tissue (muscle or liver) and other organs (brain, thyroid, 
heart, lung, kidney, stomach, intestine, colon, bone, 
blood and skin) were sampled. The samples were 
weighed separately and then evaluated for radioactivity 
using an automatic gamma counter (Perkin Elmer; 2470 
WIZARD2; USA). Corrections were made for background 
radiation and physical decay during quantification. 
The radioactivity of the samples was calculated as 
the percentage of the injected dose per gram of tissue 
(ID%/g). Biodistribution of 131I-Hyp was expressed by the 
radioactivity (ID%/g) of different organs at the last time 
point.
Autoradiography
The tumor together with its surrounding tissue 
was resected and prepared as cryostat serial sections. 
Autoradiography was performed using 10-μm unstained 
sections with the Molecular Imager FX System (Bio-
Rad laboratories, UK). The sections were exposed for 
24 hours to a storage phosphor screen, which was then 
read by a scanner. The acquired autoradiographic images 
were analyzed using Quantity One 4.3.1 software (Bio-
Rad, UK). The intensity of radioactivity was measured by 
placing a square region of interest (2 mm2) on different 
positions of color-coded images. Next, the sections 
were stained with hematoxylin and eosin (H&E) for 
conventional light microscopy.
Fluorescence microscopy
Fluorescence images were acquired on 5-μm 
unstained cryostat sections by fluorescence microscopy 
(Nikon ECLIPSE 80i, Japan) using an excitation 
wavelength of 510–560 nm (Hyp excited wavelength). 
The fluorescent intensities of central necrosis, viable 
rim and peritumoral tissue were measured and analyzed 
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by NIS-Elements D software (Nikon, Japan). Next, the 
sections were stained with H&E.
Statistical analysis
Numerical data were expressed as the mean ± 
standard deviation. Statistical analysis was performed 
using Graphpad Prism (La Jolla, CA, USA) 5.0 software 
demo. One-way ANOVA was used to test differences 
between tumor volumes and TDT among the groups. 
Unpaired Student’s t test (two-tailed) was performed 
to compare the tumor area, intensity of radioactivity 
and fluorescence intensity between different tissues, 
and a p value less than 0.05 was considered statistically 
significant.
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